The filing contains no unexpected material information; traders should focus on upcoming quarterly earnings reports to assess execution against the $627.5M guidance midpoint.
GKOS drugs
GKOS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 4 $135.85entry
- T+1 · 7mo ago −1.79%α −2.58% · $133.42
- T+5 · 6mo ago −0.35%α −3.29% · $135.37
- T+20 · 6mo ago −24.09%α −29.74% · $103.12
- T+60 · 4mo ago +19.00%α +17.14% · $161.66
Price Chart
How similar events traded
Executive Summary
Glaukos Corp filed an 8-K attaching its May 2026 investor presentation, which reiterates financial highlights including 2025 net sales of $507M, 2026 revenue guidance midpoint of $627.5M, 84% gross margin, $281M cash with no debt, and a 10-year revenue CAGR of 20%. The presentation is a standard corporate update with no material new disclosures, so the filing is routine and non-eventful.
Key Facts
- 2025 net sales: $507 million (up from $383M in 2024)
- 2026 revenue guidance midpoint: $627.5 million
- Gross margin (1Q 2026): 84%
- Cash and equivalents: $281 million; no debt as of 3/31/2026
- 10-year revenue CAGR: 20%
- R&D investment since 2018: $800 million
Financial Impact
No new financial impact; previously disclosed guidance and results reaffirmed.
Risk Factors
- Pipeline execution and regulatory approvals (e.g., iDose TRIO, Epioxa adoption)
- Competitive pressures in interventional glaucoma and keratoconus markets
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-202466 |
| Document: d135093d8k.htm | 0001193125-26-202466 |
| Document: 0001193125-26-202466-index-headers.html | 0001193125-26-202466 |
| Document: 0001193125-26-202466-index.html | 0001193125-26-202466 |
| Document: 0001193125-26-202466.txt | 0001193125-26-202466 |
Track record
16 reports on GKOS
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $242.67 Now $244.88 +0.91% settles Nov 23
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $245.72 Now $244.88 −0.34% settles Nov 20
- Nov 6, 202610d ago 8-K Neutral 3/10 Entry $224.41 to $245.72 Now $244.88 +9.12% ▲ +9.50% +6.90% vs SPY
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $224.41 to $245.72 Now $244.88 +9.12% ▲ +9.50% +6.90% vs SPY
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $246.70 to $247.16 Now $244.88 −0.74% ▲ +0.19% +1.10% vs SPY
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $246.70 to $247.16 Now $244.88 −0.74% ▲ +0.19% +1.10% vs SPY
- Oct 30, 202617d ago 144 Neutral 3/10 Entry $237.60 to $224.41 Now $244.88 +3.06% ▼ −5.55% −2.85% vs SPY
- Oct 28, 202619d ago 8-K Bullish 6/10 Entry $242.48 to $219.98 Now $244.88 +0.99% ▼ −9.28% −4.55% vs SPY
- Aug 13, 202613w ago Insider Cluster Neutral 3/10 Entry $184.53 to $184.89 Now $244.88 +32.70% ▲ +0.20% +1.56% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 2/10 Entry $186.63 to $189.55 Now $244.88 +31.21% ▲ +1.56% +2.01% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers